EP0258339A1 - Emploi de tanins et/ou d'acide chlorogene, ainsi que stimulants, aliments et/ou medicaments avec addition de tanin et/ou d'acide chlorogene - Google Patents

Emploi de tanins et/ou d'acide chlorogene, ainsi que stimulants, aliments et/ou medicaments avec addition de tanin et/ou d'acide chlorogene

Info

Publication number
EP0258339A1
EP0258339A1 EP87901423A EP87901423A EP0258339A1 EP 0258339 A1 EP0258339 A1 EP 0258339A1 EP 87901423 A EP87901423 A EP 87901423A EP 87901423 A EP87901423 A EP 87901423A EP 0258339 A1 EP0258339 A1 EP 0258339A1
Authority
EP
European Patent Office
Prior art keywords
gastric
tannins
chlorogenic acid
acid
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP87901423A
Other languages
German (de)
English (en)
Inventor
Claus F. GÖSSWEIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Code Kaffee-Handelsgesellschaft MbH
Original Assignee
Code Kaffee-Handelsgesellschaft MbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Code Kaffee-Handelsgesellschaft MbH filed Critical Code Kaffee-Handelsgesellschaft MbH
Publication of EP0258339A1 publication Critical patent/EP0258339A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F5/00—Coffee; Coffee substitutes; Preparations thereof
    • A23F5/10—Treating roasted coffee; Preparations produced thereby
    • A23F5/14—Treating roasted coffee; Preparations produced thereby using additives, e.g. milk, sugar; Coating, e.g. for preserving
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings

Definitions

  • Tannin or catechin-based tannin agents and / or isolated chlorogenic acid or their physiologically compatible deriv tives have the effect, when used before or during the absorption of foodstuffs, stimulants and / or medicines which activ the secretion of gastric acid and / or irritate or attack the gastric mucous membrane, of reducing the secretion of gastric ac and / or of protecting the gastric mucous membrane.
  • Tannins based on tannin or catechin and / or isolated chlorogenic acid or their physiologically tolerable derivatives lead, when used, before or at the same time as the administration of food, food and / or / which stimulates gastric acid secretion and / or irritates or attacks the gastric mucosa. or medicines to reduce gastric acid secretion and / or to protect the gastric mucosa.
  • tannins and / or chlorogenic acid as well as food, luxury foods and / or medicinal products with added tannins and / or chlorogenic acid
  • duodenal ulcer, ventricular ulcer and other gastric mucosal lesions which are often stress and / or medication-induced, can bleed or perforate in a life-threatening manner.
  • Non-steroidal anti-inflammatory drugs NSAIDs
  • NSAIDs Non-steroidal anti-inflammatory drugs
  • acetylsalicylic acid can lead to gastric bleeding; the same applies to the other NSAIDs, e.g. Indomethacin (see R. Bruhn et al., Progress in Medicine 100 (36), 1661 to 168 (1982)).
  • Therapy with acetylsalicylic acid and other drugs from the NSAID group carries a defined risk, so that before using these drugs, their therapeutic benefits must be weighed against the accompanying risk.
  • the invention is therefore based on the object of finding a means by which the gastric mucosa can be protected against the development of ulcerations in such a way that food, luxury foods and / or medications that damage the gastric mucosa can be administered without disturbing side effects up to life-threatening bleeding and perforations.
  • tannins based on tannins or catechins or agents based on isolated chlorogenic acid or their physiologically tolerable derivatives are suitable for protecting the gastric mucosa against food, luxury foods and / or drugs who are known to damage the gastric and duodenal mucosa or to stimulate gastric acid secretion.
  • the tannins or the chlorogenic acid are applied before or simultaneously with the administration of the agents mentioned.
  • chlorogenic acid means the mono- and dicaffeoylquinic acids and mixtures thereof.
  • the 3-, 4- and 5-caffeoylquinic acids or their mixture, in particular the 3-caffeoylquinic acid, are particularly preferred.
  • the acids can be used as free acid or in the form of their physiologically compatible derivatives, in particular salts or esters.
  • the alkali salts, especially the potassium salts, are particularly suitable.
  • the derivatives mentioned can be used instead of the free acid, since the acid is released from them in the strongly acidic gastric environment.
  • Chlorogenic acid is a compound found in numerous plants, for example in green coffee beans, which was isolated by Freudenberg in 1920, the structure of which has been elucidated, and which was later also synthesized (see Merck Index, 10th edition, No. 2112). From a publication by V. Istudor et al., Farmacia 29, 41 to 48 (1981) it is known that a from Calendulae
  • Flores available extract can be used as stomach tea for the treatment of gastric and duodenal ulcers. It is reported that the extract includes Contains alantoin, caffeinic acid and polyphenol derivatives, including chlorogenic acid. Chlorogenic acid is said to be a choleretic and cholagogue. A synergism between the different components of the examined extract is suspected.
  • chlorogenic acid as a pure substance has a protective effect on the gastric mucosa. This is apparently due to the fact that under the action of chlorogenic acid a superficial protective film is formed which protects the gastric mucosa. At the same time, the stimulated gastric acid secretion decreases. These effects may be due to an astringent or tanning effect of chlorogenic acid, similar to that of tanning agents.
  • the hydrolyzable ester-like tannins and / or their derivatives are particularly preferred as tanning agents.
  • These tannins are esters of sugars, especially glucose, with various hydroxybenzoic acids, especially 3, 4, 5-trihydroxybenzoic acid (gallic acid).
  • the non-ester-like, condensed tannins which are primarily compounds from the group of catechins, such as those found in tea, can also be used.
  • the various tannins are commercially available; as a rule, these are mixtures of compounds which are obtained from natural raw materials.
  • the tannins are known to have an astringent and hemostatic effect. They are used externally as hemostatic agents and for the treatment of local burns (sunburn). It is also known to use tannins Treatment of diarrhea, ie to use catarrhal diseases of the intestinal tract. For this purpose, tannins for complexes with protein (tannin albumin) are used in order to ensure that the tannin is only released in the intestine, that is, it is not yet effective in the stomach.
  • tannins for complexes with protein tannins for complexes with protein (tannin albumin) are used in order to ensure that the tannin is only released in the intestine, that is, it is not yet effective in the stomach.
  • tannins or chlorogenic acid are able to protect the gastric or duodenal mucosa from aggressive foodstuffs, foods and medicines which stimulate acid secretion.
  • the agents according to the invention form a whitish, net-like coating immediately after contact with the mucous membrane, which acts like a protective film.
  • 10% alcohol is applied as an irritant, there is no change in the area protected in this way, while the untreated gastric mucosa shows pathological reddening.
  • the tannins or the chlorogenic acid are preferably prepared in such a way that they are released only in the stomach. This can be done in a manner known per se by using a coating in the manufacture of tablets which only dissolves in the acidic gastric environment.
  • the agents can be administered either before or preferably at the same time as the agents against which the gastric mucosa is to be protected. As far as it concerns foodstuffs or stimulants, it concerns those which contain practically no tannins or chlorogenic acid or an insufficient amount thereof, but which are converted into a more stomach-friendly form by the addition according to the invention can be.
  • the invention is of particular importance in connection with active pharmaceutical ingredients which damage the gastric mucosa in such a way that ulcers or bleeding can occur.
  • a particular problem in this regard is acetylsalicylic acid and the other NSAIDs, which many patients take regularly as an analgesic or anti-rheumatic and can then lead to the side effects described in the gastrointestinal tract.
  • acetylsalicylic acid or the other NSAID with tannins and / or chlorogenic acid in a dosage form that releases the active substances in the gastric juice, the gastric mucosa can be effectively protected, with the result that gastric mucosal lesions or bleeding are no longer observed.
  • the combination preparations according to the invention are preferably administered to fasting patients in order to prevent the added tannins from being rendered ineffective by reaction with proteins from the diet.
  • a particularly favorable dosage form e.g. in the form of a core / shell tablet with the active substance as the core and the protective substances (tannins and / or chlorogenic acid) in the outer shell
  • first the tannin or chlorogenic acid and then the active substance are released.
  • the test subjects received 250 ml of coffee samples 1 to 5.
  • the gastric juice extracted at time 0 was returned.
  • 5 ml gastric juice were siphoned off.
  • the gastric juice was then quantitatively removed at intervals of 15 minutes.
  • the titratable acid determined with 0.1N NaOH, in Table 2 the values found are given in ml NaOH.
  • the volume of gastric juice extracted is given in Table 2 in ml.
  • the period t 60-150 was used for the comparative evaluation of the results, since it is known that the first 60 minutes after eating are overlaid by various other effects.
  • Coffee samples Nos. 1 to 5 had an identical degree of roasting, but contained increasing amounts of chlorogenic acid. As the results shown in Table 2 show, coffee 1 leads to the highest acid stimulation, with increasing chlorogenic acid content the gastric acid secretion decreases significantly. Volume secretion also decreases in the order of coffee types 1 to 5. The influence of chlorogenic acid on the reduction of human gastric acid secretion stimulated by coffee roasting agents is obvious.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Des matières tannantes à base de tanin ou de catéchine, et/ou de l'acide chlorogène isolé ou leurs dérivés physiologiquement compatibles ont pour effet, en cas d'emploi précédant ou accompagnant l'absorption d'aliments, de stimulants et/ou de médicaments activant la sécrétion d'acide gastrique et/ou irritant ou attaquant la muqueuse gastrique, de réduire la sécrétion d'acide gastrique et/ou de protéger la muqueuse gastrique.
EP87901423A 1986-02-06 1987-02-03 Emploi de tanins et/ou d'acide chlorogene, ainsi que stimulants, aliments et/ou medicaments avec addition de tanin et/ou d'acide chlorogene Withdrawn EP0258339A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19863603576 DE3603576A1 (de) 1986-02-06 1986-02-06 Verwendung von gerbstoffen und/oder chlorogensaeure sowie nahrungs-, genuss- und/oder arzneimittel mit gerbstoff- und/oder chlorogensaeurezusatz
DE3603576 1986-02-06

Publications (1)

Publication Number Publication Date
EP0258339A1 true EP0258339A1 (fr) 1988-03-09

Family

ID=6293456

Family Applications (1)

Application Number Title Priority Date Filing Date
EP87901423A Withdrawn EP0258339A1 (fr) 1986-02-06 1987-02-03 Emploi de tanins et/ou d'acide chlorogene, ainsi que stimulants, aliments et/ou medicaments avec addition de tanin et/ou d'acide chlorogene

Country Status (7)

Country Link
US (1) US4865847A (fr)
EP (1) EP0258339A1 (fr)
JP (1) JPS63502349A (fr)
DE (1) DE3603576A1 (fr)
DK (1) DK524087A (fr)
FI (1) FI874361A0 (fr)
WO (1) WO1987004619A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3760463D1 (en) * 1986-02-06 1989-09-28 Code Kaffee Handel Coffee and process for its production
DE69109286T2 (de) * 1990-05-03 1995-09-28 Searle & Co Pharmazeutische zusammensetzung.
US5629013A (en) * 1991-04-04 1997-05-13 The Procter & Gamble Company Chewable calcium carbonate antacid tablet compositions
FR2693105B1 (fr) * 1992-07-01 1994-09-02 Oreal Composition cosmétique et/ou dermatologique à action dépigmentante contenant un acide di- ou tri-caféoylquinique ou un mélange de ceux-ci.
TW255880B (fr) * 1992-09-09 1995-09-01 Hoechst Ag
US6696485B1 (en) 1996-04-02 2004-02-24 Mars, Incorporated Procyanidin and cyclo-oxygenase modulator compositions
AU4147800A (en) * 1999-04-13 2000-11-14 Biosynergen, Inc. Composition for preventing or treating dementia comprising hydroxycinnamic acid derivative or an extract of a plant of genus (angelicae) containing same
CN100548304C (zh) * 2000-03-22 2009-10-14 马尔斯公司 应用与乙酰水杨酸联合的可可矢车菊苷配质作为抗血小板疗法
WO2002076456A1 (fr) * 2001-03-27 2002-10-03 Nutricia, N.V. Procede permettant d'inhiber l'apoptose de cellules souches
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
JP2006160721A (ja) * 2004-11-09 2006-06-22 Kao Corp 大脳疲労回復剤
KR20110079641A (ko) 2008-09-09 2011-07-07 아스트라제네카 아베 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법
SG176724A1 (en) 2009-06-25 2012-01-30 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
EP2340808A1 (fr) * 2009-12-21 2011-07-06 I.R.B. Istituto Di Ricerche Biotecnologiche S.r.l. Combinaison synergique de phénylpropanoïdes, tels que la verbascoside ou la teupolioside, et la mésalamine
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
EP2756765B1 (fr) * 2013-01-17 2019-03-27 Symrise AG Compositions pharmaceutiques
CN103360435B (zh) * 2013-06-09 2016-09-07 陕西师范大学 一种响应面法优化山茱萸果核中鞣质的提取工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES407523A1 (es) * 1971-10-13 1975-11-16 Robins Co Inc A H Un procedimiento para la preparar un coprecitado de un agenteantiinflamatorio y acido tanico.
IL43512A0 (en) * 1972-10-25 1974-03-14 Robins Co Inc A H Aspirin-tea coprecipitates and their preparation
US4003999A (en) * 1972-10-25 1977-01-18 A. H. Robins Company, Incorporated Aspirin-tea coprecipitates for treating inflammation
GB1509979A (en) * 1975-11-28 1978-05-10 Fisons Ltd Pharmaceutical compositions containing aspirin or indomethacin
DE2657896C3 (de) * 1976-12-21 1979-12-06 Dobrivoje Dr. 8000 Muenchen Tomic Mittel mit blutstillender und entzündungshemmender Wirkung
JPS60192555A (ja) * 1984-03-13 1985-10-01 Osaka Chem Lab 抗アレルギ−食品
JPS60243016A (ja) * 1984-05-17 1985-12-03 Tsumura Juntendo Inc 抗インフルエンザウイルス剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8704619A1 *

Also Published As

Publication number Publication date
WO1987004619A1 (fr) 1987-08-13
JPS63502349A (ja) 1988-09-08
FI874361A (fi) 1987-10-05
DK524087D0 (da) 1987-10-06
DK524087A (da) 1987-10-06
FI874361A0 (fi) 1987-10-05
US4865847A (en) 1989-09-12
DE3603576A1 (de) 1987-08-13

Similar Documents

Publication Publication Date Title
AT401346B (de) Verfahren zur herstellung eines antioxidationsmittels, insbesondere zur verwendung als arzneimittel
DE3705151C2 (fr)
EP0258339A1 (fr) Emploi de tanins et/ou d'acide chlorogene, ainsi que stimulants, aliments et/ou medicaments avec addition de tanin et/ou d'acide chlorogene
DE60132851T2 (de) Arzneimittel zur Vorbeugung, Linderung oder Behandlung von Hypertonie
EP2057994A1 (fr) Préparation d'extrait de cactus à figues
EP2135616B1 (fr) Fruit d'airelle séché destiné à influencer l'état de l'intestin
CA2077589A1 (fr) Extrait stimulant l'activite cerebrale
DD238920A5 (de) Verfahren zur herstellung einer verbesserten entzuendungshemmend wirkenden zusammensetzung
DE2606533A1 (de) Therapeutisches mittel
EP2817002B1 (fr) Combinaison de protéines de transfert lipidique et de dérivés phénoliques contenant des substances végétales localement efficaces sur les muqueuses
DE19716660A1 (de) Zubereitungen, insbesondere pharmazeutische, und Arzneiformen auf pflanzlicher Basis zur Bekämpfung von Heliobacter pylori-Infektionen
JP2002020278A (ja) 口腔ガン予防用チューインガム
DE2342460A1 (de) Eisen- oder aluminiumglycyrrhizinat enthaltendes produkt, verfahren zu seiner herstellung und dieses produkt enthaltendes arzneimittel
WO1991008750A1 (fr) Utilisation de parties de la plante naturelle tinospora
EP1001756A1 (fr) Compositions a effet synergique pour lutter selectivement contre les tissus tumoraux
KR101084727B1 (ko) 더덕 추출물 또는 더덕 사포닌을 포함하는 히스타민 분비 억제용 조성물
JPH03145430A (ja) 抗炎症用組成物
DE102018127408A1 (de) Cranberry-Extrakt-PAC-A-Zusammensetzung und dessen Verwendung bei der Prävention und/oder Behandlung von Harnwegsinfekten
JP2002080385A (ja) 金属沈着抑制剤
DE19839443A1 (de) Arnzneimittel mit entzündungshemmender Wirkung
LU500687B1 (de) Nahrungs- oder diätische zusammensetzung
DE3117756A1 (de) "theophyllin-tablette"
DE69723417T2 (de) Propolis Extrakt mit verbesserter Wasserlöslichkeit
RU2053782C1 (ru) Способ лечения язвенно-некротического стоматита
EP0291751B1 (fr) Préparation pharmaceutique constituée par un mélange

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19871027

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19891129

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19900410

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GOESSWEIN, CLAUS, F.